Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn’s disease

Horace RT Williams¹,¹, I Jane Cox², David G Walker¹, Jeremy FL Cobbold¹, Simon D Taylor-Robinson¹, Sara E Marshall³, Timothy R Orchard¹

Abstract

Background: Certain urinary metabolites are the product of gut microbial or mammalian metabolism; others, such as hippurate, are mammalian-microbial ‘co-metabolites’. It has previously been observed that Crohn’s disease (CD) patients excrete significantly less hippurate than controls. There are two stages in the biosynthesis of this metabolite: 1) gut microbial metabolism of dietary aromatic compounds to benzoate, and 2) subsequent hepatorenal conjugation of benzoate with glycine, forming hippurate. Differences in such urinary co-metabolites may therefore reflect systemic consequences of altered gut microbial metabolism, though altered host metabolic pathways may also be involved.

Methods: It was hypothesised that reduced hippurate excretion in CD patients was due to alterations in the gut microbiota, and not differences in dietary benzoate, nor defective host enzymatic conjugation of benzoate. 5 mg/kg sodium benzoate were administered orally to 16 CD patients and 16 healthy controls on a low-benzoate diet. Baseline and peak urinary hippurate excretion were measured.

Results: Baseline hippurate levels were significantly lower in the CD patients (p = 0.0009). After benzoate ingestion, peak urinary levels of hippurate did not differ significantly between the cohorts. Consequently the relative increase in excretion was significantly greater in CD (p = 0.0007).

Conclusions: Lower urinary hippurate levels in CD are not due to differences in dietary benzoate. A defect in the enzymatic conjugation of benzoate in CD has been excluded, strongly implicating altered gut microbial metabolism as the cause of decreased hippurate levels in CD.

Background

The pathogenesis of the inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC), is thought to involve a genetically-determined, abnormal host immune response to an environmental stimulus, which is likely to be bacterial [1]. There is compelling evidence that dysbiosis of the commensal enteric microbes plays an important role in the pathogenesis of these diseases [2]. Urinary metabolite levels are strongly influenced by differences in the intestinal microbiota, since both gut bacterial metabolism, and shared metabolism by the host and bacterial species (‘co-metabolism’), generate specific metabolic products [3]. Such metabolites may therefore be used as markers of microbial metabolic activity, reflecting systemic, functional differences. This application of urinary metabolic profiling avoids the technical difficulties, and methodological differences, found in molecular studies of the intestinal microbiota in IBD, which have contributed to often discrepant findings [4].

It has previously been shown that urinary levels of the host-bacterial co-metabolite, hippurate, are significantly lower in IBD patients when compared to healthy control individuals, most significantly in those with CD (p < 0.0001) [5]. These differences were independent of medication, disease location and disease activity.
Differences in urinary co-metabolites may reflect altered gut microbial metabolism, though altered host metabolic pathways may also be implicated. This study was undertaken to investigate the biosynthesis of hippurate in IBD, and specifically to clarify the influence of the gut microbiota on urinary hippurate excretion.

The origins of hippuric acid have been investigated since the compound was first identified in urine by Liebig in 1829 [6]. By the early 20th century, it had been established that in man, hippurate is the product of the conjugation of benzoate with glycine [7]. Later investigations revealed that this conjugation occurs via the formation of an intermediate, benzoyl CoA [8], and that it takes place in the mitochondria [9] of the liver and the kidney [10]. Animal experiments have shown that urinary hippurate excretion is modulated according to the composition of the intestinal microbiome [11,12].

The biosynthesis of hippurate is shown diagrammatically in (Figure 1). It is excreted at millimolar concentrations in human urine.

Benzoate, a simple carboxylic acid, is produced from the microbial degradation of dietary aromatic compounds in the intestine, such as polyphenols, purines, and aromatic organic acids and amino acids [13-15]. Consequently, hippurate excretion has been shown to increase following the intake of black, green and chamomile tea [16,17] as well as a diet rich in fruit and vegetables [18]. Benzoate itself is also present in various foodstuffs and drinks. It is present naturally in most berries, fruits and fermented dairy products [19]. Due to their antimicrobial properties, both benzoic acid and benzoate salts may be used as preservatives. While common additives around the world, in the United Kingdom these compounds are little used, though may be found in soft drinks, sauces and reduced-sugar jams [20].

Early reports noted that hippurate production after benzoate ingestion appeared to eliminate nitrogen that would otherwise have been excreted as urea [7]. This has been applied clinically in the management of hepatic encephalopathy, at a dose of 10 g per day [21], and in the treatment of patients with urea cycle enzymopathies in therapeutic dosages of 150-500 mg/kg body weight per day [22]. Consequently, more recent experiments have investigated the pharmacokinetics of benzoate in relation to its use in the treatment of disease, concluding that the substrate exhibits Michaelis-Menten kinetics [23]. The saturable nature of this metabolism at very high doses, due to limitations in the availability of glycine, has been demonstrated [23,24].

The metabolism and elimination of low doses of benzoate occurs rapidly, with the peak response of urinary hippurate excretion within 1-2 hrs of ingestion [25], for at low doses saturation of the metabolic pathway does not occur. A World Health Organization review suggested a No-Observed-(Adverse)-Effect-Level of about 500 mg/kg body weight [26]. This incorporated an uncertainty factor of 100, and recommended a provisional, chronic acceptable intake of 5 mg/kg body weight per day.

Rationale for the study
Elucidating the metabolism and biosynthesis of hippurate may provide insights into intestinal microbial dysbiosis in IBD.

There are two steps to the production of urinary hippurate from dietary sources. Firstly, the metabolism of dietary aromatic compounds to benzoate by the gut microbiota and secondly, the subsequent conjugation of benzoate with glycine to form hippurate. Hippurate excretion is reduced in IBD cohorts [5]. Since the most
significant differences were observed in the CD cohort, it was these patients rather than UC patients who were chosen for inclusion in the current study. It is known that the gut microbes in CD differ from the healthy population [27], and so it was hypothesised that an alteration in the intestinal microbiota was responsible for the variation in hippurate excretion.

To confirm that the reduced urinary hippurate was not due to differences in dietary benzoate, foods known to contain high concentrations of natural benzoate, its precursors, or benzoate as a preservative, were excluded from the diet.

In order to exclude a defect in benzoate conjugation in IBD as the cause of reduced urinary hippurate levels, sodium benzoate was administered orally to groups of healthy control individuals and CD patients. It was hypothesised that, after benzoate ingestion, the increase in urinary hippurate would be similar in the two cohorts, and so the increase would be relatively greater in the CD population, whose baseline levels of hippurate are lower.

Methods

Subjects
The study was approved by the St. Mary’s Research Ethics Committee (Ref 08/H0712/35) and all participants gave written, informed consent.

Patients with CD and healthy individuals were invited to participate: vegetarians and those on a therapeutic diet for IBD were considered ineligible, due to the likely influence on urinary metabolite levels [18]. Patients with significant comorbidity or a history of orofacial granulomatosis (the treatment of which may involve a benzoate-free diet) were excluded from the study [28]. Individuals with an intercurrent illness, who were pregnant, or who were taking antibiotics, pre- or probiotics were also excluded.

Studies have shown that a minority of patients with CD has increased intestinal permeability, and it has been suggested that this is correlated with disease activity [29]. Urinary hippurate levels were in fact lower in the previously studied CD cohort [5], making increased permeability unlikely as the cause for the observed differences. The differences in urinary hippurate also persisted whether disease was active or quiescent. Nonetheless, all of the CD participants in the current experiment were studied in remission as defined by the Harvey-Bradshaw Index [30].

Dosage of sodium benzoate used for the study
To determine the dose of benzoate to be administered for the study, a review of the literature was undertaken [7,23-25,31] and a pilot experiment was carried out in a healthy control individual, using nuclear magnetic resonance (NMR) spectroscopy to quantify urinary hippurate as described previously [5].

It was established that, after a dose of the WHO recommended maximum daily intake of benzoate (5 mg/kg body weight), there was an easily detectable increase in urinary hippurate excretion at 1 hr post-dose, and that by 2 hrs post-dose the urinary hippurate concentration had decreased to near baseline values. Hence a dose of 5 mg/kg body weight was chosen.

Study Protocol

Dietary restrictions
After agreeing to participate, each individual was asked to avoid, for 24 hrs, specific drinks and foodstuffs known to contain high levels of benzoic acid/sodium benzoate, or significantly to influence hippurate synthesis through the metabolism of other organic acids. These were: black, green or herbal teas, fruit and carbonated drinks, berries, pickles and yoghurt.

Subjects were asked to provide a dietary and lifestyle history, as previously described [5], to ensure that there were no significant differences between the cohorts which could influence results.

Sodium benzoate administration
Participants were asked to give a random, mid-stream urine sample between 10.00 and 14.00 hrs. A dose of 5 mg/kg body weight sodium benzoate was then administered in the form of ‘Amzoate’ Sodium Benzoate Oral Liquid (sugar free, Dales Pharmaceuticals Ltd, UK for Special Products Ltd, UK) and subjects were asked to provide urine samples at 1 and 2 hrs post-dose. During this period, they were requested not to eat or drink.

¹H NMR spectroscopy of urine samples
A standard technique for the preparation of urine samples was used [5]. This involved mixing 400 μL of each sample with 200 μL of 0.2 M phosphate buffer, pH 7.35, to stabilize pH. Any precipitates were removed by subsequent centrifugation. 500 μL of supernatant were then mixed with 50 μL of 3-trimethylsilyl-(2,2,3,3-²H₄)-1-propionate (TSP)/D₂O solution. The TSP served as an internal chemical shift reference (δ 0.00 ppm) and the D₂O provided a field lock.

Samples were analysed blinded, in a random order. 1 D spectra were acquired using a JEOL 500 MHz Eclipse+ NMR spectrometer and a standard protocol with water presaturation. The spectral width was 15 ppm and the number of data points acquired was 64 K. A pulse-collect sequence was used with a 90° pulse angle. The acquisition time was 8.74 s. A relaxation delay of 10 s (total repetition time 18.74 s) ensured full relaxation between data collects. The 16 data collects were summated.
Spectra were processed using the KnowItAll Informatics System v7.8 (Bio-Rad, Philadelphia, USA). Free induction decays were zero-filled by a factor of two and multiplied by an exponential window function with a 0.3 Hz line-broadening factor prior to Fourier transformation. Spectra were phased and a baseline correction applied.

**Statistical analysis**

Resonances corresponding to hippurate (δ 7.83 ppm, doublet) were integrated and normalized to the sum of the total spectral integral. Values were expressed as a relative index, to the total spectral integral, corrected for the number of contributory protons (2H); values were also expressed as mmol/mol creatinine (δ 4.07 ppm, singlet, 2H).

Hippurate levels in the CD and control cohorts, pre-dose, were compared using the Mann-Whitney U test. Comparisons between the paired samples of each individual were made using the Wilcoxon signed rank test. Peak hippurate excretion values for the CD and control cohorts (1 hr post-dose) were compared using the Mann-Whitney U test.

The peak hippurate excretion value for each participant at 1 hr post-dose was subtracted from the baseline value, and the resulting figure, representing the absolute difference in hippurate level, was compared between the CD and control cohorts. The increase in hippurate level as a percentage change was also calculated.

Dietary and lifestyle data from the cohorts were analysed using the Mann-Whitney U test for continuous variables and Fisher’s exact test or chi-square test (as appropriate) for categorical variables.

**Results**

**Subject groups**

Subject demographics, and details of disease for the CD cohort [32], are shown in (Table 1). Two cohorts of 16 participants were recruited. The median age of the CD cohort was non-significantly higher than the control cohort. Three of the CD patients were taking no medication.

There were no significant differences between the groups with regards to dietary constituents, smoking, alcohol intake or exercise. Female subjects were matched for hormonal status.

None of the participants reported side-effects of the benzoate ingestion.

**Sample collection**

For all subjects, baseline (pre-dose) and peak response samples, at 1 hr, were collected. In both cohorts, excretion of urinary hippurate was highest at 1 hr post-dose, and had decreased by 2 hrs. The baseline and peak response values were used for analysis of conjugating ability.

**Baseline hippurate levels**

A comparison was made between hippurate levels in the CD and control cohorts at baseline (ie. on the diet as described above) to negate the possible effect of foods and drinks containing either endogenous benzoate, or containing benzoate as a preservative, on hippurate excretion. The results are shown in(Figure 2). As hypothesised, significant differences were observed.

### Table 1 Participant characteristics

|                   | Crohn’s disease | Healthy controls |
|-------------------|-----------------|------------------|
| Number (Male/Female) | 16 (7/9)        | 16 (9/7)         |
| Median [range] age (years) | 42 [22-66]     | 33 [22-62]      |
| Disease location  | L1: 2           | -                |
|                   | L2: 6           | -                |
|                   | L3: 8           | -                |
| Previous bowel resection | 6              |                  |

L1 = ileal disease, L2 = colonic disease, L3 = ileocolonic disease [32].

### Figure 2 Baseline urinary hippurate levels

Expressed relative to total spectral integral. Median and interquartile ranges shown; p = 0.0009, Mann-Whitney U test.
between the cohorts. The dietary restrictions of this study in fact had little impact on urinary hippurate values: the median values (relative to the total spectral integral) in this study for the CD and control cohorts were 0.39 u and 0.97 u respectively, compared to 0.38 u and 1.04 u in the previous study [5].

Expressed as mmol/mol creatinine, results of a similar statistical significance were obtained, hippurate levels being lower in the CD cohort: median (interquartile range) 113 (61-182) mmol/mol creatinine vs. 242 (143-365) mmol/mol creatinine, p = 0.007.

**Hippurate excretion after benzoate ingestion**

The increase in hippurate excretion after the ingestion of 5 mg/kg benzoate for the CD and control groups is shown in (Figure 3). It can be seen that the baseline values for the control cohort were significantly greater than those for the CD cohort, and that the values for peak excretion at 1 hr increased more dramatically for the CD cohort. The peak excretion values did not differ significantly between the healthy control subjects and CD patients (Figure 4), nor were there significant differences in the absolute difference in hippurate excretion (calculated as the value at baseline subtracted from the value at 1 hr, (Figure 5A). As may be inferred from these figures, the percentage change in hippurate excretion was significantly greater in the CD than the control cohort (p = 0.0007, Figure 5B).

Expressed as mmol/mol creatinine, results were very similar: peak excretion values did not differ (p = 0.34), nor did the absolute differences in hippurate excretion (p = 0.25). The percentage change in hippurate excretion was greater in the CD cohort (p = 0.0006).

**Discussion**

This experiment has confirmed the previous finding of reduced urinary hippurate levels in CD. It has demonstrated that the difference in urinary hippurate between CD and controls is not due differences in ingested benzoate, and that patients with CD do not have an intrinsic defect in the conjugation of benzoate with glycine. This implicates alterations in the gut microbiota in the observed differences in hippurate excretion.

The influence of diet on the excretion of urinary hippurate has been demonstrated in previous studies [17,18,33], emphasising the need for a careful evaluation of dietary components when analysing urinary metabolic data in the context of disease. As shown in (Figure 2), the reduced excretion of hippurate in CD patients persisted when foods known to contain high levels of benzoic acid/sodium benzoate, or to influence hippurate synthesis through the metabolism of other organic acids, were excluded from the diet. This finding supports the contention that it is the generation of benzoate via the intestinal microbial metabolism of dietary aromatic compounds that primarily influences the differences in urinary hippurate between the cohorts.
To ensure that the reduced levels of urinary hippurate excretion in CD were not due to an intrinsic defect in hippurate metabolism, this experiment investigated the ability of a CD cohort to conjugate benzoate with glycine, in comparison to a healthy control cohort. A dose of 5 mg/kg of sodium benzoate was administered to all participants, and it was found that the peak excretion of the metabolic product, urinary hippurate, occurred at 1 hr post-dose. There have been no published studies investigating the excretion of hippurate after the ingestion of this dose of benzoate, but inspection of the data from two previous studies, one using much higher doses [23] and another using lower doses [25] suggests that these results are compatible.

Kubota and Ishizaki, after studying the excretion of hippurate after extreme doses of 40, 80 and 160 mg/kg sodium benzoate, deduced that the biotransformation of benzoic to hippuric acid follows saturable, or Michaelis-Menten kinetics, with a maximum rate of biotransformation of 23 mg.kg^{-1}.h^{-1} [23]. At a dose of 5 mg/kg, as employed in the current study, the metabolically active enzymatic components of the pathway and endogenous glycine, rather than the substrate (benzoate), are in great excess. Consequently, in the presence of an intact enzymatic conjugation pathway, the CD cohort had a relatively higher production of hippurate because baseline levels were significantly lower: as seen in (Figure 5B), this was the salient finding of the study.

Thus, although the baseline hippurate levels were lower in the CD cohort, the absolute difference in hippurate excretion from baseline to peak excretion (1 hr post-benzoate administration) was not significantly different between the cohorts, and the percentage change in hippurate excretion of the CD patients was significantly greater than that of the controls. These results demonstrate that there is no deficit in the conjugation pathway in CD patients.

The concentration of urinary hippurate has been shown to be modulated according to the composition of the intestinal microbiota [11,12]. The findings of this study provide additional evidence for the systemic effects of an altered gut microbiome in IBD, notably identifying a functional metabolic consequence of the dysbiosis.

A recent study in healthy individuals has given further insights into the powerful influence exerted by the gut bacteria in the determination of human metabolic phenotypes [34]. A reduction in Clostridia spp. has been consistently shown in IBD, and particularly CD [4]; Li et al. [34] found a positive association between Clostridia spp. and hippurate levels, which may account for the reduced hippurate levels in our study. Future studies correlating the urinary metabolic profiles of IBD patients with molecular analysis of their gut microbiota would be of great interest, representing an avenue for further research.

Recently, Brahmachari et al. have investigated the anti-inflammatory properties of benzoate in the context of glial cell activation [35]. In experimental animals, benzoate, but not formate, inhibited glial activation of NFκB
and expression of inducible NO synthase and pro-inflammatory cytokines. Reduced synthesis of benzoate by the intestinal microbiota in IBD may thus be implicated in the pathogenesis of the disease; further experiments in models of intestinal inflammation are warranted.

Conclusions

In conclusion, the biosynthesis and excretion of urinary hippurate has been investigated in cohorts of CD patients and healthy control individuals. The data presented provide strong evidence for the pivotal role of the gut microbiota in the generation of urinary hippurate and, moreover, their influence on the differences in hippurate excretion between CD patients and healthy control individuals.

Acknowledgements

The authors thank Dr. Bernard North (Imperial College Statistical Advisory Service) and Dr. Neil Chapman (Clinical Pharmacology, Imperial College Healthcare NHS Trust) for helpful discussions. The authors acknowledge the generous support of the Broad Medical Research Program (Grant Number IBD-0187) and St Mary’s Paddington Charitable Trustees, and Procter and Gamble for a contribution to additional laboratory expenses. HRTW, UC, DGW, JFLC, SDR-T and TRO are grateful to the NIHR Biomedical Facility at Imperial College London for infrastructure support.

Author details

1Gastroenterology and Hepatology Section, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, St Mary’s Hospital Campus, Imperial College London, London, UK 2Imaging Sciences Department, MRC Clinical Sciences Centre, Hammersmith Hospital Campus, Imperial College London, London, UK 3Department of Immunology, University of Dundee, Dundee, UK

Authors’ contributions

HRTW, UC, JFLC, SDR-T, SEM and TRO were responsible for the study design and co-ordination. Samples were collected and prepared by HRTW and DGW. NMR spectroscopy was performed by UC, HRTW, DGW and JFLC. HRTW analysed the data with IJC and TRO. HRTW drafted the report. All authors have approved the final draft submitted.

Competing interests

The authors declare that they have no competing interests.

Received: 22 July 2010 Accepted: 17 September 2010 Published: 17 September 2010

References

1. Sartor RB: Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:390-407.
2. Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
3. Nicholson JK, Holmes E, Wilson ID: Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005, 3:431-438.
4. Sokol H, Lay C, Selsk P, Tannock GW: Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 2008, 14:858-867.
5. Williams HR, Cox U, Walker DG, North BV, Patel VM, Marshall SE, Jewell DP, Ghosh S, Thomas HJ, Teare JP, Jakobovits S, Zeki S, Welsh RJ, Taylor-Robinson SD, Orchard TR: Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 2009, 104:1435-1444.
6. Liebig J: Über die Säure, welche in dem Harne der gasfressenden vierfussigen Thiere enthalten ist. Poggendorf Ann Phys Chem 1829, 17:389-399.
7. Lewis HB: Studies in the synthesis of hippuric acid in the animal organism. II. The synthesis and rate of elimination of hippuric acid after benzoate ingestion in man. J Biol Chem 1914, 18:225-231.[http://www.jbc.org/content/18/2/225.full.pdf].
8. Schacht D, Taggart Jv: Benzoyl coenzym A and hippuric synthesis. J Biol Chem 1953, 203:925-934.
9. Gatley SJ, Sherratt HS: The synthesis of hippurate from benzoate and glycine by rat liver mitochondria. Submitochondrial localization and kinetics. Biochem J 1977, 166:9-47.
10. Caldwell J, Moffatt JR, Smith RL: Post-mortem survival of hippuric acid formation in rat and human cadaver tissue samples. Xenobiotica 1976, 6:275-280.
11. Williams RE, Eyton-Jones HW, Farnworth MU, Gallagher R, Provan WM: Effect of intestinal microflora on the urinary metabolic profile of rats: a 1H nuclear magnetic resonance spectroscopy study. Xenobiotica 2002, 32:783-794.
12. Nicholls AW, Mortshire-Smith RJ, Nicholson JK: NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. Chem Res Toxicol 2003, 16:1395-1404.
13. Rechner AR, Kuhnle G, Brenner P, Hubbard GR, Moore KP, Rice-Evans CA: The metabolic fate of dietary polyphenols in humans. Free Radic Biol Med 2002, 33:220-235.
14. Gibson DT: Microbial degradation of aromatic compounds. Science 1967, 161:1093-1097.
15. Nicholson JK, Wilson ID: Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2003, 2:2669-2676.
16. Mulder TP, Retveld AG, van Armelsoort JM: Consumption of both black tea and green tea results in an increase in the excretion of hippuric acid into urine. Am J Clin Nutr 2005, 81(1 Suppl):285S-260S.
17. Wang Y, Tang H, Nicholson JK, Hyland DJ, Sampson J, Holmes E: A metabonomic strategy for the detection of the metabolic effects of chamomile (Matricaria recutita L.) ingestion. J Agric Food Chem 2003, 51:191-196.
18. Walsh MC, Brennan L, Puigs-Guillot E, Sebedio JL, Scalbert A, Fagan A, Higgins DG, Gibney MJ: Influence of acute physiologically reactive intake on human urinary metabolomic profiles. Am J Clin Nutr 2007, 86:1687-1693.
19. Sieber R, Butikofer U, Bossert JO: Benzoic acid as a natural product in cultured dairy products and cheese. Int Dairy Journal 1995, 5:227-246.
20. UK MAFF: Survey of sulphur dioxide and benzoic acid in foods and drinks. Food Surveillance Information Sheet No 65 London, Ministry of Agriculture, Fisheries and Food, Joint Food Safety and Standards Group. 1995 [http://archive.food.gov.uk/maff/archive/food/infsheet/j/1995/65sulben.htm].
21. Suthina S, Dacarathy S, Tandon RK, Jain S, Gupta S, Bhist MS: Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992, 16:1384-144.
22. Brusilow SW, Valle DL, Bhatnaw M: New pathways of nitrogen excretion inborn errors of urea synthesis. Lancet 1979, 2:8140(452-454.
23. Kubota I, Ishihara T: Dose-dependent pharmacokinetics of benzoic acid following oral administration of sodium benzoate to humans. Eur J Clin Pharmacol 1991, 41:363-368.
24. Quick AJ: The conjugation of benzoic acid in man. J Biol Chem 1931, 92:65-85 [http://www.jbc.org/content/92/1/65.full.pdf].
25. Cathcan-Rake W, Porter R, Whitter F, Stein P, Carey M, Grantham J: Effect of diet on serum accumulation and renal excretion of asy acids and secretory activity in normal and uremic man. Am J Clin Nutr 1975, 28:1110-1115.
26. Wibbertmann A, Kiellom J, Koeneneger G, Mangelsdorf I, Melber C: Benzoic acid and sodium benzoate. Concise International Chemical Assessment Document 26. World Health Organisation 2000 [http://www.inchem.org/documents/cid/cid26.htm].
27. Subramanian S, Campbell BJ, Rhodes JM: Bacteria in the pathogenesis of inflammatory bowel disease. Curr Opin Infect Dis 2006, 19:475-484.
28. White A, Nunes C, Escudier M, Lomer MC, Barnard K, Shirlaw P, Challacombe SJ, Sanderson JD: Improvement in orofacial granulomatosis on a cinnamon- and benzoate-free diet. Inflamm Bowel Dis 2006, 12:508-514.
29. Adenis A, Colombel JF, Lecouffe P, Wallaert B, Hecquet B, Marchandise X, Cortot A: Increased pulmonary and intestinal permeability in Crohn’s disease. Gut 2002, 33:678-682.
30. Harvey RF, Bradshaw JW: A simple index of Crohn’s disease activity. Lancet 1980, 1(8167):514.
31. Bridges JW, French MR, Smith RL, Williams RT: The fate of benzoic acid in various species. Biochem J 1970, 118:47-51.
32. Silverberg MS, Satsangi J, Ahmad T, Amott BD, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Perka AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermiere S, Warren BF: Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
33. van Dorsten FA, Daykin CA, Mulder TP, van Duynhoven JP: Metabonomics approach to determine metabolic differences between green tea and black tea consumption. J Agric Food Chem 2006, 54:6929-6938.
34. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, Zhang M, Wei H, Chen Y, Lu H, Zuo J, Su M, Qiu Y, Jia W, Xiao C, Smith LM, Yang S, Holmes E, Tang H, Zhao G, Nicholson JK, Li L, Zhao L: Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008, 105:2117-2122.
35. Brahmacari S, Jana A, Pahan K: Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 2009, 183:5917-5927.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/10/108/prepub

doi:10.1186/1471-230X-10-108
Cite this article as: Williams et al: Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn’s disease. BMC Gastroenterology 2010 10:108.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit